Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02272049 · ClinicalTrials.gov registry record · Phase 1
Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
A Phase 1 study of Respiratory Disorders, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT02272049 is a Phase 1 study of Respiratory Disorders that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02272049, a Phase 1 study of Respiratory Disorders, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the usefulness of hyperpolarized (HP) 129Xe (xenon) gas MRI for regional assessment of lung function in a normal population of children and adults and in adults and also in children with respiratory compromise due to a variety of diseases.
Conditions Studied
Interventions
- DRUG Hyperpolarized 129 Xenon
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2014-12 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02272049
The ClinicalTrials.gov registry entry for NCT02272049 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Disorders appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 129 Xenon is the first listed.
NCT02272049 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02272049 about?
NCT02272049 is a clinical study titled "Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults". The goal of this study is to evaluate the usefulness of hyperpolarized (HP) 129Xe (xenon) gas MRI for regional assessment of lung function in a normal population of children and adults and in adults and also in children with respiratory compromise due to a variety of diseases.
What is the current status of trial NCT02272049?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2014-12. Estimated completion is 2029-08-31.
What conditions does trial NCT02272049 study?
This clinical trial studies the following conditions: Respiratory Disorders.
What interventions are being tested in trial NCT02272049?
The interventions under investigation include: Hyperpolarized 129 Xenon (DRUG).
Who is sponsoring clinical trial NCT02272049?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02272049 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration
RECRUITING · Phase 1
-
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.